LANGUAGE
History of KAINOS
Kainos has a long history of contributing to medical care and preventive medicine. It is a history of analyzing the needs of the medical field and market trends, developing original products, and providing them to the world. The following is a chronological introduction of Kainos’ history of anticipating changes in the clinical diagnostics industry.
1975
| May. | DOMS-IATRON Co., Ltd. (currently Kainos) was established with a capital stock of 30,000,000 yen as a developer of new products in the health care industry. |
|---|---|
| Jul. | Changed its name to Kainos Laboratories, Inc. |
| Sep. | Released the world’s first enzyme-based serum transaminase measurement reagent kit. |
1976
| Dec. | Formed a technical tie-up with Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin,Ltd.) on enzyme immunoassay method (EIA). |
|---|
1981
| Apr. | Entered into a technical tie-up agreement with Hitachi Chemical Co., Ltd.(Currently Hitachi Chemical Diagnostics Systems Co., Ltd.) on reagents for clinical analysis equipment. |
|---|
1983
| Mar. | Entered into a sales agreement for blood transfusion diagnostics products with GAMMA BIOLOGICALS, Inc (USA) |
|---|---|
| Apr. | Released an enzyme-based creatinine measurement reagent kit.
|
1987
| Jun. | Entered into a technical tie-up agreement with Nippon Kayaku Co., Ltd. on clinical examination reagents. |
|---|
1992
| Sep. | Entered into a technical tie-up agreement with Kirin Beer Co., Ltd. (Currently Kyowa Kirin Co., Ltd.) on clinical examination reagents. |
|---|
1993
| Mar. | Moved production to Kasama Factory, and began production of biochemical and immunoserological reagents. |
|---|---|
| Oct. | Entered into a technical tie-up agreement with Asahi Chemical Industry Co., Ltd. (Currently Asahi Kasei Pharma Corporation) on clinical examination reagents.
|
1995
| Oct. | Moved the Head Office to Hongo, Bunkyo-ku, Tokyo. |
|---|---|
| Dec. | Listed on JASDAQ.
|
2000
| Jun. | Acquired ISO 9001 certification, an international standard for quality assurance. |
|---|---|
| Oct. | Entered into the licence agreement of NASBA Patents with Organon Teknika B. V.(Ownership of the “NASBA Gene Amplification” patent has been transferred from Organon Teknika B.V. to bioMerieux.) |
2004
| May. | Entered into a distributorship agreement for genetic products with bioMerieux Japan. |
|---|---|
| Nov. | Launched marketing of an influenza detection reagent “Statmark™ Influenza A/B” that had been jointly developed by Nichirei Corporation (currently Nichirei Bioscience Inc,) and Kainos. |
2005
| Jul. | Created Kainos BB, Co. Ltd. by spinning out Kainos’ Blood Banking business (in June 2005) then changed the name of the spun out company to Immucor-Kainos, Inc. through a joint venture agreement established as a part of the ongoing collaborative effort between Immucor, Inc. and Kainos. |
|---|
2006
| May. | Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment. |
|---|
2007
| Oct. | Acquired ISO 13485 certification, an international standard for quality assurance of in vitro medical equipment. |
|---|
2008
| Apr. | Introduction of the Kainos Executive Office System. Established Compliance Center. |
|---|---|
| May. | Kainos-Immucor, Inc.’s (currently K. K. Immucor) stocks were transferred to Immucor, Inc. |
2011
| Sep. | Entered into a distributorship agreement for blood transfusion diagnostics products with Grifols SA. |
|---|
2018
| Feb. | Insurance coverage granted to the assays respectively measuring two fractions of blood carnitine using blood carmitine measuring reagents based on the enzyme cycling method. |
|---|---|
| Apr. | Insurance coverage granted to the diagnostic drug based on an ADAMTS13 activity measurement reagent for the thrombotic thrombocytopenic purpura.
|
2019
| May. | Concluded a share transfer agreement with Asahi Kasei Pharma Corporation to further enhance the mutual business relationship. |
|---|
2020
| Sep. | Capital tie-up with Gene Therapy Research Institution Co.,Ltd. by accepting a part of its third-party allotment of shares. |
|---|
2022
| Feb. | Concluded a capital and business tie-up with Sysmex Corporation to further enhance the mutual business relationship. |
|---|